Full Press Release Details
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.
| Solebury Trout 2021 Virtual Investor Conference | ||
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer | |
| Date: | January 11-15, 2020 | |
| Access: | Available on demand at the following Link | |
| H.C. Wainwright BioConnect 2021 Virtual Conference | ||
| Speakers: | Gilad Mamlok, Chief Financial Officer | |
| Date: | January 11-14, 2020 | |
| Access: | Available on demand to conference participants. |
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Chief Financial Officer
Source: Sol-Gel Technologies Ltd.